Mucopolysaccharidosis Type I (MPS I) stands as a paradigm for how innovative medical research can transform the outlook for rare genetic disorders. This lysosomal storage disease, characterized by alpha-L-iduronidase enzyme deficiency, affects multiple organ systems and presents significant clinical challenges. However, the evolution of treatment strategies has revolutionized patient care, offering unprecedented therapeutic options that… Read.